Roivant Sciences Ltd. $ROIV Shares Purchased by Retirement Systems of Alabama

Retirement Systems of Alabama raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 19.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 558,777 shares of the company’s stock after purchasing an additional 92,427 shares during the quarter. Retirement Systems of Alabama owned 0.08% of Roivant Sciences worth $20,434,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ROIV. Waverly Advisors LLC boosted its position in shares of Roivant Sciences by 2.3% during the second quarter. Waverly Advisors LLC now owns 12,869 shares of the company’s stock valued at $455,000 after buying an additional 291 shares during the last quarter. Fifth Third Bancorp grew its holdings in Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after buying an additional 376 shares in the last quarter. Signaturefd LLC raised its position in Roivant Sciences by 10.9% in the 3rd quarter. Signaturefd LLC now owns 4,487 shares of the company’s stock valued at $164,000 after buying an additional 440 shares during the last quarter. Bessemer Group Inc. raised its position in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the last quarter. Finally, Versant Capital Management Inc raised its position in Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after buying an additional 487 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $41.85 on Thursday. The company’s 50-day moving average is $37.09 and its 200 day moving average is $32.08. Roivant Sciences Ltd. has a fifty-two week low of $19.96 and a fifty-two week high of $42.50.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $36.31, for a total value of $7,262,000.00. Following the sale, the chief executive officer owned 999,154 shares of the company’s stock, valued at approximately $36,279,281.74. The trade was a 16.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the completion of the sale, the insider directly owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. This represents a 0.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 2,022,688 shares of company stock worth $73,438,636. Insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the topic of a number of analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. Guggenheim increased their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. HC Wainwright increased their target price on shares of Roivant Sciences from $47.00 to $48.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Finally, Bank of America restated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.64.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.